The mexican cervical cancer screening trial: Self-sampling for human papillomavirus with unaided visual inspection as a secondary screen

Jerome L. Belinson, Robert G. Pretorius, Christine Enerson, Francisco A Garcia, Eduardo Pérez Cruz, Suzanne E. Belinson, Eduardo Yeverino García, Jennifer Brainard

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The Mexican Cervical Cancer Screening (MECCS) study took place in the State of Michoacán. Primary screening was by self-sampling for high-risk human papillomavirus (HR-HPV). The objectives were to increase the specificity of primary HPV screening by requiring 2 positive HPV tests 1 year apart in women whose secondary screen was negative according to an acetic acidYaided visual inspection (VIA). In addition, we postulated that the sensitivity of VIAwould be sufficient to identify large preinvasive lesions and cancers unsuitable for cryotherapy if applied in a see-and-treat algorithm. A total of 8621 women (aged 30-50 years) were screened, and 14.3% were positive for HR-HPV. In phase 1, 11.9% of the HPV-positive women were VIA-positive and were referred for colposcopy with directed and random biopsies. If VIA-negative, women repeated the self-sample 1 year later to detect persistent HR-HPV (25.2% were positive). If persistently HR-HPVYpositive in phase 2, patients again had VIA, then all women (both VIA-positive and -negative) received directed and random biopsies. If cryotherapy had been used to treat HPV- and VIA-positivewomen in phase 1 or persistent HR-HPVYpositive (phase 2), the potential risk of undertreatment would have been 4.1%, and 66.4% of the treated patients would have had normal or cervical intraepithelial neoplasia I on biopsy. The VIA triage would refer 0.73% of the patients to colposcopy owing to the lesion size, location, or the presence of a cancer. On the basis of this pilot study, we are encouraged to explore and evaluate a rapid, more sensitive, and more specific self-test.

Original languageEnglish (US)
Pages (from-to)27-32
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume19
Issue number1
DOIs
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

Early Detection of Cancer
Uterine Cervical Neoplasms
Colposcopy
Cryotherapy
Biopsy
Cervical Intraepithelial Neoplasia
Triage
Acetic Acid
Neoplasms

Keywords

  • HPV
  • Screening
  • Self-sampling

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Medicine(all)

Cite this

The mexican cervical cancer screening trial : Self-sampling for human papillomavirus with unaided visual inspection as a secondary screen. / Belinson, Jerome L.; Pretorius, Robert G.; Enerson, Christine; Garcia, Francisco A; Cruz, Eduardo Pérez; Belinson, Suzanne E.; García, Eduardo Yeverino; Brainard, Jennifer.

In: International Journal of Gynecological Cancer, Vol. 19, No. 1, 01.2009, p. 27-32.

Research output: Contribution to journalArticle

Belinson, Jerome L. ; Pretorius, Robert G. ; Enerson, Christine ; Garcia, Francisco A ; Cruz, Eduardo Pérez ; Belinson, Suzanne E. ; García, Eduardo Yeverino ; Brainard, Jennifer. / The mexican cervical cancer screening trial : Self-sampling for human papillomavirus with unaided visual inspection as a secondary screen. In: International Journal of Gynecological Cancer. 2009 ; Vol. 19, No. 1. pp. 27-32.
@article{cb83520ef48a4d43bc347ebcb836ab48,
title = "The mexican cervical cancer screening trial: Self-sampling for human papillomavirus with unaided visual inspection as a secondary screen",
abstract = "The Mexican Cervical Cancer Screening (MECCS) study took place in the State of Michoac{\'a}n. Primary screening was by self-sampling for high-risk human papillomavirus (HR-HPV). The objectives were to increase the specificity of primary HPV screening by requiring 2 positive HPV tests 1 year apart in women whose secondary screen was negative according to an acetic acidYaided visual inspection (VIA). In addition, we postulated that the sensitivity of VIAwould be sufficient to identify large preinvasive lesions and cancers unsuitable for cryotherapy if applied in a see-and-treat algorithm. A total of 8621 women (aged 30-50 years) were screened, and 14.3{\%} were positive for HR-HPV. In phase 1, 11.9{\%} of the HPV-positive women were VIA-positive and were referred for colposcopy with directed and random biopsies. If VIA-negative, women repeated the self-sample 1 year later to detect persistent HR-HPV (25.2{\%} were positive). If persistently HR-HPVYpositive in phase 2, patients again had VIA, then all women (both VIA-positive and -negative) received directed and random biopsies. If cryotherapy had been used to treat HPV- and VIA-positivewomen in phase 1 or persistent HR-HPVYpositive (phase 2), the potential risk of undertreatment would have been 4.1{\%}, and 66.4{\%} of the treated patients would have had normal or cervical intraepithelial neoplasia I on biopsy. The VIA triage would refer 0.73{\%} of the patients to colposcopy owing to the lesion size, location, or the presence of a cancer. On the basis of this pilot study, we are encouraged to explore and evaluate a rapid, more sensitive, and more specific self-test.",
keywords = "HPV, Screening, Self-sampling",
author = "Belinson, {Jerome L.} and Pretorius, {Robert G.} and Christine Enerson and Garcia, {Francisco A} and Cruz, {Eduardo P{\'e}rez} and Belinson, {Suzanne E.} and Garc{\'i}a, {Eduardo Yeverino} and Jennifer Brainard",
year = "2009",
month = "1",
doi = "10.1111/IGC.0b013e318197f479",
language = "English (US)",
volume = "19",
pages = "27--32",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The mexican cervical cancer screening trial

T2 - Self-sampling for human papillomavirus with unaided visual inspection as a secondary screen

AU - Belinson, Jerome L.

AU - Pretorius, Robert G.

AU - Enerson, Christine

AU - Garcia, Francisco A

AU - Cruz, Eduardo Pérez

AU - Belinson, Suzanne E.

AU - García, Eduardo Yeverino

AU - Brainard, Jennifer

PY - 2009/1

Y1 - 2009/1

N2 - The Mexican Cervical Cancer Screening (MECCS) study took place in the State of Michoacán. Primary screening was by self-sampling for high-risk human papillomavirus (HR-HPV). The objectives were to increase the specificity of primary HPV screening by requiring 2 positive HPV tests 1 year apart in women whose secondary screen was negative according to an acetic acidYaided visual inspection (VIA). In addition, we postulated that the sensitivity of VIAwould be sufficient to identify large preinvasive lesions and cancers unsuitable for cryotherapy if applied in a see-and-treat algorithm. A total of 8621 women (aged 30-50 years) were screened, and 14.3% were positive for HR-HPV. In phase 1, 11.9% of the HPV-positive women were VIA-positive and were referred for colposcopy with directed and random biopsies. If VIA-negative, women repeated the self-sample 1 year later to detect persistent HR-HPV (25.2% were positive). If persistently HR-HPVYpositive in phase 2, patients again had VIA, then all women (both VIA-positive and -negative) received directed and random biopsies. If cryotherapy had been used to treat HPV- and VIA-positivewomen in phase 1 or persistent HR-HPVYpositive (phase 2), the potential risk of undertreatment would have been 4.1%, and 66.4% of the treated patients would have had normal or cervical intraepithelial neoplasia I on biopsy. The VIA triage would refer 0.73% of the patients to colposcopy owing to the lesion size, location, or the presence of a cancer. On the basis of this pilot study, we are encouraged to explore and evaluate a rapid, more sensitive, and more specific self-test.

AB - The Mexican Cervical Cancer Screening (MECCS) study took place in the State of Michoacán. Primary screening was by self-sampling for high-risk human papillomavirus (HR-HPV). The objectives were to increase the specificity of primary HPV screening by requiring 2 positive HPV tests 1 year apart in women whose secondary screen was negative according to an acetic acidYaided visual inspection (VIA). In addition, we postulated that the sensitivity of VIAwould be sufficient to identify large preinvasive lesions and cancers unsuitable for cryotherapy if applied in a see-and-treat algorithm. A total of 8621 women (aged 30-50 years) were screened, and 14.3% were positive for HR-HPV. In phase 1, 11.9% of the HPV-positive women were VIA-positive and were referred for colposcopy with directed and random biopsies. If VIA-negative, women repeated the self-sample 1 year later to detect persistent HR-HPV (25.2% were positive). If persistently HR-HPVYpositive in phase 2, patients again had VIA, then all women (both VIA-positive and -negative) received directed and random biopsies. If cryotherapy had been used to treat HPV- and VIA-positivewomen in phase 1 or persistent HR-HPVYpositive (phase 2), the potential risk of undertreatment would have been 4.1%, and 66.4% of the treated patients would have had normal or cervical intraepithelial neoplasia I on biopsy. The VIA triage would refer 0.73% of the patients to colposcopy owing to the lesion size, location, or the presence of a cancer. On the basis of this pilot study, we are encouraged to explore and evaluate a rapid, more sensitive, and more specific self-test.

KW - HPV

KW - Screening

KW - Self-sampling

UR - http://www.scopus.com/inward/record.url?scp=65649129309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649129309&partnerID=8YFLogxK

U2 - 10.1111/IGC.0b013e318197f479

DO - 10.1111/IGC.0b013e318197f479

M3 - Article

C2 - 19258937

AN - SCOPUS:65649129309

VL - 19

SP - 27

EP - 32

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 1

ER -